Cargando…

Predictive P-score for treatment ranking in Bayesian network meta-analysis

BACKGROUND: Network meta-analysis (NMA) is a widely used tool to compare multiple treatments by synthesizing different sources of evidence. Measures such as the surface under the cumulative ranking curve (SUCRA) and the P-score are increasingly used to quantify treatment ranking. They provide summar...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenberger, Kristine J., Duan, Rui, Chen, Yong, Lin, Lifeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520624/
https://www.ncbi.nlm.nih.gov/pubmed/34657593
http://dx.doi.org/10.1186/s12874-021-01397-5
_version_ 1784584707997958144
author Rosenberger, Kristine J.
Duan, Rui
Chen, Yong
Lin, Lifeng
author_facet Rosenberger, Kristine J.
Duan, Rui
Chen, Yong
Lin, Lifeng
author_sort Rosenberger, Kristine J.
collection PubMed
description BACKGROUND: Network meta-analysis (NMA) is a widely used tool to compare multiple treatments by synthesizing different sources of evidence. Measures such as the surface under the cumulative ranking curve (SUCRA) and the P-score are increasingly used to quantify treatment ranking. They provide summary scores of treatments among the existing studies in an NMA. Clinicians are frequently interested in applying such evidence from the NMA to decision-making in the future. This prediction process needs to account for the heterogeneity between the existing studies in the NMA and a future study. METHODS: This article introduces the predictive P-score for informing treatment ranking in a future study via Bayesian models. Two NMAs were used to illustrate the proposed measure; the first assessed 4 treatment strategies for smoking cessation, and the second assessed treatments for all-grade treatment-related adverse events. For all treatments in both NMAs, we obtained their conventional frequentist P-scores, Bayesian P-scores, and predictive P-scores. RESULTS: In the two examples, the Bayesian P-scores were nearly identical to the corresponding frequentist P-scores for most treatments, while noticeable differences existed for some treatments, likely owing to the different assumptions made by the frequentist and Bayesian NMA models. Compared with the P-scores, the predictive P-scores generally had a trend to converge toward a common value of 0.5 due to the heterogeneity. The predictive P-scores’ numerical estimates and the associated plots of posterior distributions provided an intuitive way for clinicians to appraise treatments for new patients in a future study. CONCLUSIONS: The proposed approach adapts the existing frequentist P-score to the Bayesian framework. The predictive P-score can help inform medical decision-making in future studies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12874-021-01397-5.
format Online
Article
Text
id pubmed-8520624
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-85206242021-10-20 Predictive P-score for treatment ranking in Bayesian network meta-analysis Rosenberger, Kristine J. Duan, Rui Chen, Yong Lin, Lifeng BMC Med Res Methodol Research BACKGROUND: Network meta-analysis (NMA) is a widely used tool to compare multiple treatments by synthesizing different sources of evidence. Measures such as the surface under the cumulative ranking curve (SUCRA) and the P-score are increasingly used to quantify treatment ranking. They provide summary scores of treatments among the existing studies in an NMA. Clinicians are frequently interested in applying such evidence from the NMA to decision-making in the future. This prediction process needs to account for the heterogeneity between the existing studies in the NMA and a future study. METHODS: This article introduces the predictive P-score for informing treatment ranking in a future study via Bayesian models. Two NMAs were used to illustrate the proposed measure; the first assessed 4 treatment strategies for smoking cessation, and the second assessed treatments for all-grade treatment-related adverse events. For all treatments in both NMAs, we obtained their conventional frequentist P-scores, Bayesian P-scores, and predictive P-scores. RESULTS: In the two examples, the Bayesian P-scores were nearly identical to the corresponding frequentist P-scores for most treatments, while noticeable differences existed for some treatments, likely owing to the different assumptions made by the frequentist and Bayesian NMA models. Compared with the P-scores, the predictive P-scores generally had a trend to converge toward a common value of 0.5 due to the heterogeneity. The predictive P-scores’ numerical estimates and the associated plots of posterior distributions provided an intuitive way for clinicians to appraise treatments for new patients in a future study. CONCLUSIONS: The proposed approach adapts the existing frequentist P-score to the Bayesian framework. The predictive P-score can help inform medical decision-making in future studies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12874-021-01397-5. BioMed Central 2021-10-17 /pmc/articles/PMC8520624/ /pubmed/34657593 http://dx.doi.org/10.1186/s12874-021-01397-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Rosenberger, Kristine J.
Duan, Rui
Chen, Yong
Lin, Lifeng
Predictive P-score for treatment ranking in Bayesian network meta-analysis
title Predictive P-score for treatment ranking in Bayesian network meta-analysis
title_full Predictive P-score for treatment ranking in Bayesian network meta-analysis
title_fullStr Predictive P-score for treatment ranking in Bayesian network meta-analysis
title_full_unstemmed Predictive P-score for treatment ranking in Bayesian network meta-analysis
title_short Predictive P-score for treatment ranking in Bayesian network meta-analysis
title_sort predictive p-score for treatment ranking in bayesian network meta-analysis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520624/
https://www.ncbi.nlm.nih.gov/pubmed/34657593
http://dx.doi.org/10.1186/s12874-021-01397-5
work_keys_str_mv AT rosenbergerkristinej predictivepscorefortreatmentrankinginbayesiannetworkmetaanalysis
AT duanrui predictivepscorefortreatmentrankinginbayesiannetworkmetaanalysis
AT chenyong predictivepscorefortreatmentrankinginbayesiannetworkmetaanalysis
AT linlifeng predictivepscorefortreatmentrankinginbayesiannetworkmetaanalysis